This work demonstrates that radiopharmaceuticals [18F]FB-Gol1 and [18F]FB-GR20 bind to rat 101.8 glioblastoma and can serve as promising drug candidates for the selective diagnosis of EGFR expression in glial tumors. Here, EGFR is linked to glioma.